Transcript 8. Ole Olesen - STOA

An Overview of European
Commission Activities on
Infectious Diseases
Ole Olesen
Unit Infectious Diseases and Public Health
Directorate-General for Research and Innovation
European Commission
STOA – Aviesan Workshop, Bruxelles – 19 June 2012
Research and
Innovation
The role of the European Commission Research and innovation
Develop and implement the European research and innovation policy
agreed by the European Parliament and European Council.
Funds research through multi-annual framework programmes for research
(since 1984).
7th Framework Programme (2007-2013) has a total budget of 53 billion €
- 4% of the total EU budget.
The European Commission manages about 5% of total public spending in
R&D in the European Union.
Policy
Research and
Innovation
The 7th EU Framework Programme (2007-2013)
Total funding:
€ 53 billion
Policy
Research and
Innovation
The power of collaboration
EU27
4
Main policy drivers:
Improving
health of
European
citizens
Increasing
competitiveness
of European healthrelated industries
Policy
Research and
Innovation
Global
health issues,
incl. emerging
epidemics
Objectives for Infectious Diseases in FP7:
to improve prevention, diagnostics and treatment
of infectious diseases by supporting scientific
collaboration between
• Countries
• Sectors – public and private
• Area of research
Approximate annual average budget for infectious
diseases in FP7: €100 million
Policy
Research and
Innovation
Key priorities for infectious diseases in
the Health Theme
• Emerging infectious diseases
 Influenza and other emerging diseases
(incl vector-borne diseases)
• Anti-microbial resistance
• Poverty-related diseases
 HIV/AIDS, Tuberculosis, malaria
• Neglected Infectious diseases
Policy
Research and
Innovation
Distribution in FP7 – so far
Neglected infectious
diseases
Projects: 15
EU contribution: € 65 M
Antimicrobial resistance
Projects: 26
EU contribution: € 131 M
Emerging infectious
diseases (incl. influenza)
Projects: 29
EU contribution: € 141 M
HIV/AIDS, malaria,
tuberculosis
Projects: 51
EU contribution: € 206 M
Policy
Research and
Innovation
FP7-funded projects
on antimicrobial resistance
“EU Research on Antimicrobial Resistance”
presents a selection of these projects:
• Bacterial infections:
20 projects
• Viral infections:
7 projects
• Protozoan infections:
4 projects
• Fungal infections:
1 project
26 projects in the Health Theme: €131 Mio
http://ec.europa.eu/research/health
>>Infectious Diseases >>Anti-Microbial Drug Resistance
Policy
Research and
Innovation
Co-operation between EU Member
States: Joint programming on AMR
•
Pulls together national research efforts, uses public
resources better, and tackles key common
challenges
•
Initiative lead by Sweden
•
18 Countries BE, CH, CZ, DE, DK, ES, FI, FR, GR,
IL, IT, NL, NO, PL, RO, SE,TK and UK involved
•
Only 2 countries (DE and NL) have earmarked
programmes for AMR research funding – the others
fund AMR research as a result of bottom-up
competition.
•
Development of a common vision and strategic
research agenda – expected this year
•
Implementation of joint activities in 2013?
Policy
Research and
Innovation
Emerging infectious
diseases (including
influenza)
29 projects with total EC funding of €141M
16 projects exclusively on human influenza €49M
3 projects on influenza and other emerging pathogens €36M
10 projects on emerging diseases excluding influenza €56M
Policy
Research and
Innovation
HIV / AIDS
Disease burden
(DALY/year 1000s)
Global
prevalence
Annual
deaths
58 513
34 million
1.8 million
Key goals in HIV/AIDS research: 18 projects, €84million
•
•
•
•
•
•
•
Basic science
Drug discovery
Vaccines
Microbicides
Diagnostics
Clinical management/treatment
Overarching ERA-NET
3
3
5
1
2
4
1
projects, €1.5M
projects, €8.5M
projects, €32.0M
projects, €12.5M
projects, €2.0M
projects, €24.0M
project,
€2.0M
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva
UNAIDS World AIDS day report, 2011
Policy
Research and
Innovation
Tuberculosis
Disease burden
(DALY/year 1000s)
Global
prevalence
Annual
deaths
34 217
13.9 million
1.464
million
Key goals in tuberculosis research: 15 projects, €66 million
•
•
•
•
•
Basic science/host-pathogen interaction
Drug discovery
Vaccines
Diagnostics
Clinical management/public health
7
3
2
2
1
projects, €14.5M
projects, €21.0M
projects, €12.5M
projects, €6.0M
project, €12.0M
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.
Policy
Research and
Innovation
Malaria
Disease burden
(DALY/year 1000s)
Global
prevalen
ce
Annual
deaths
33 976
million
889 000
Key goals in malaria research: 18 projects, €56million
•
•
•
•
•
Basic science/host-pathogen interaction
Vector research
Drug discovery
Vaccines
Diagnostics
4
5
3
5
1
projects, €20.3M
projects, €20.8M
projects, €4.6M
projects, €7.4M
project, €2.8M
WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.
Policy
Research and
Innovation
Priority disease
Disease
burden
(DALY/year
1000s)
Global
prevalence
Annual
deaths
Leishmaniasis
1974
12 million
47 000
Sleeping sickness
1673
<100 000
52 000
Chagas disease
430
8-9 million
11 000
Neglected
infectious
diseases
Key goals in NID research: 15 projects, €65M
Protozoa (Leishmaniasis, Sleeping sickness, Chagas)
Bacteria (Buruli Ulcer, Diarrhoeal diseases)
Helminths (Schistosomiasis, Onchocerciasis, Filariasis)
•
•
•
•
•
Basic immunology
Vector control/public health
Drug discovery
Vaccines
Diagnostics
Policy
Research and
Innovation
5
7
6
7
3
projects,
projects,
projects,
projects,
projects,
€13.1M
€10.5M
€11.0M
€25.7M
€4.7M
WHO (2008) The
Global Burden of
Disease: 2004 Update,
World Health
Organisation, Geneva.
Hotez et al. (2009)
Lancet 373:1570-1575.
Collaborative projects improves the
European Research Infrastructure
• Coordinator: Prof. Kholoud Porter,
MRC clinical trials unit, London, UK
• Consist of 23 beneficiaries from 16
countries + more than 100 collaborating
centres
• EU contribution: € 12 M
• Unique resource
• Access to data from over 250,000 HIV
positive people
Policy
Research and
Innovation
16
16
European Developing Countries Clinical
Trials Partnership (EDCTP)
• Public-Public Partnership: Joint
initiative between 16 Member States
and European Commission,
established under art. 185
• Independent legal entity (EEIG)
• Coordination of European national
programmes for clinical trials in Africa
for HIV/AIDS, malaria, TB
200 M €
• EC contribution of 200 mill Euro +
MS contribution of 200 mill Euro
200 M €
• Launched in 2004, to be renewed
2014 (EDCTP-2)
Policy
Research and
Innovation
17
17
Innovative Medicines Initiative (IMI)
• Public-private partnership, initiative under
Article 187
• Collaboration between EC and the
European Federation of Pharmaceutical
Industries and Associations (EFPIA) as a
Joint Technology Initiative under FP7
• Objective: to make drug discovery and
development more efficient; to bring better
medicines faster to patients; and to attract
research investment to Europe
• Support / Funding of research activities
following open Calls and independent
review
Policy
Research and
Innovation
18
18
Next steps…
• FP7
• Next call for proposals under Health (to be published
in July 2012) contains new opportunities for building
research infrastructures
• Large Topics (EU contribution up to 24 M Euro) on
"Clinical management of patients in severe
epidemics"
• Medium-sized topic (EU contribution up to 6 M Euro)
on "Drug discovery platform for neglected parasitic
diseases"
Policy
Research and
Innovation
Horizon 2020
The EU Framework
Programme for
Research and Innovation
THE Future
2014-2020
20
Research and
Innovation
Three priorities:
1. Excellent science (≈ 30%)
2. Industrial leadership (≈ 30%)
3. Societal challenges (≈ 40%)
Commission has proposed €80 billion budget for 2014-2020
Legislative decision by MS and EP during 2012-2013
Horizon 2020 will start 1 January 2014
Research and
Innovation
Among the Societal Challenges identified :
HEALTH, DEMOGRAPHIC CHANGE
AND WELL-BEING
• How to provide better health, while
• maintaining an economically sustainable
healthcare system ?
• More health for the money !
Policy
Research and
Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered
•
Effective health promotion and disease prevention




Understanding the determinants of health, improving health
promotion and disease prevention
Developing effective screening programmes and improving
the assessment of disease susceptibility
Improving surveillance and preparedness of infectious
diseases
Developing better preventive vaccines and evidence-based
vaccination schemes
Policy
Research and
Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered
• Manage, treat and cure diseases and disabilities
 Understanding disease
 Improving diagnosis
 Using in-silico medicine for improving disease management and
prediction
 Treating disease
 Transferring knowledge to clinical practice
 Individual empowerments for self-management of health and
integrated care
Policy
Research and
Innovation
HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING
Main Specific Research Lines Considered
• Translating research into better healthcare
 Better use of health data
 Improving scientific tools and methods to support policy making
and regulatory needs
 Active ageing, independent and assisted living
 Optimising the efficiency and effectiveness of healthcare systems
and reducing inequalities
Policy
Research and
Innovation
Thank you
European Commission
DG Research and Innovation
Infectious Diseases and Public Health
Research and
Innovation